Neurochem Update on the North American Phase III Clinical Trial for Tramiprosate (ALZHEMED(TM)) for the Treatment of Alzheimer's Disease

    LAVAL, QC, April 19 /CNW Telbec/ - Neurochem Inc. (NASDAQ:   NRMX; TSX:
NRM) announces that the database for the North American Phase III clinical
trial for tramiprosate (ALZHEMED(TM)) for the treatment of Alzheimer's disease
has been locked. The analysis is ongoing and entails employing an accurate
statistical model that appropriately describes the data and provides accurate
results. Neurochem has been advised by its external team of statisticians that
adjustment to the initial statistical model, as set out in the statistical
plan, would be necessary to provide accurate results. The procedure to arrive
at a reliable model involves a detailed analysis of potential confounding
factors such as the effect of concomitant medications, baseline
characteristics of the study population or differences in clinical sites.
Neurochem points out that potential refinement of the statistical model was
discussed with the U.S. Food and Drug Administration before filing with the
Agency and was anticipated in the plan filed.
    The Company notes that in a clinical trial of the size, duration and
complexity of the tramiprosate (ALZHEMED(TM)) Phase III study, such a process
is not uncommon. The Company has been informed that it could take several
weeks, perhaps longer, before the results are known. Neurochem continues to
expect to announce these results during the second quarter of this year.

    About Neurochem

    Neurochem Inc. is focused on the development and commercialization of
innovative therapeutics to address critical unmet medical needs. Eprodisate
(KIACTA(TM) - formerly FIBRILLEX(TM)) is currently being developed for the
treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for
marketing approval by the United States Food and Drug Administration and
European Medicines Agency. Tramiprosate (ALZHEMED(TM)), for the treatment of
Alzheimer's disease, has completed a Phase III clinical trial in North America
and is currently in a Phase III clinical trial in Europe, while tramiprosate
(CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral
Amyloid Angiopathy, has completed a Phase IIa clinical trial.

    To Contact Neurochem

    For additional information on Neurochem and its drug development
programs, please call the North American toll-free number 1 877 680-4500 or
visit our Web Site at

    This news release contains forward-looking statements regarding
tramiprosate (ALZHEMED(TM)) as well as regarding continuing and further
development efforts. These statements are based on the current analysis and
expectations of management. Drug development necessarily involves numerous
risks and uncertainties, which could cause actual results to differ materially
from this current analysis and these expectations. Analysis regarding the
results of clinical trials may not provide definitive results regarding
safety, tolerability or therapeutic benefits. Even if all the endpoints sought
in the clinical trials were met (which is not certain), there is no certainty
that regulators would ultimately approve tramiprosate (ALZHEMED(TM)) for sale
to the public. Risks and uncertainties may include: failure to demonstrate the
safety, tolerability and efficacy of our product, that actual results may vary
once the final and quality-controlled verification of data and analyses has
been completed, the expense and uncertainty of obtaining regulatory approval,
including from the FDA, and the possibility of having to conduct additional
clinical trials. Further, even if regulatory approval is obtained, therapeutic
products are generally subject to: stringent on-going governmental regulation,
challenges in gaining market acceptance, and competition. Neurochem does not
undertake any obligation to publicly update its forward-looking statements,
whether as a result of new information, future events, or otherwise. Please
see the Annual Information Form for further risk factors that might affect the
Company and its business.

For further information:

For further information: Lise Hébert, PhD Vice President, Corporate
Communications, (450) 680-4572,

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890